This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Elsabagh, S. Articles by File, S. E. Search for Related Content PubMed PubMed Citation Articles by Elsabagh, S. Articles by File, S. E. Social Bookmarking                   What's this?

Limited cognitive benefits in Stage +2 postmenopausal women after 6 weeks of treatment with Ginkgo biloba

Psychopharmacology Research Unit, Centre for Neuroscience, King’s College London, London and Centre for Pharmacognosy and Phytotherapy, The School of Pharmacy, London, UK, sarah.elsabagh{at}kcl.ac.uk

David E. Hartley

Psychopharmacology Research Unit, Centre for Neuroscience, King’s College London, London, UK

Sandra E. File

Psychopharmacology Research Unit, Centre for Neuroscience, King’s College London, London, UK

Gingko biloba has cognitive benefits both in populations suffering from dementia and after acute treatment in healthy volunteers, with some evidence indicating that those with poorer cognitive performance show greater benefit. We have previously found that 1 week of treatment with ginkgo improved attention, memory and mental flexibility in post-menopausal women, but the evidence for any beneficial effects of longer treatment is less well-established. The present study aimed to determine whether cognitive benefits, similar to those previously found after 1 week of treatment, would persist after 6 weeks of treatment, and whether those with poorer cognitive performance would benefit more. In a placebo-controlled, double-blind study, postmenopausal women (aged 51-67 years) were randomly allocated to receive a standardized extract of ginkgo (LI 1370, Lichtwer Pharma, Marlow, UK) (one capsule/day of 120 mg, n = 45) or matching placebo (n = 42) for 6 weeks. According to an established reproductive staging system, subjects were divided into those in the early (Stage +1; mean age 55 years) and late (Stage +2: mean age 61 years) stages of menopause. At baseline and after 6 weeks of treatment, subjects completed tests of mental flexibility, planning, memory and sustained attention, and ratings of mood, sleepiness, bodily and menopausal symptoms. The only significant effects of ginkgo were in the test of mental flexibility, in which there were significant menopausal stage-ginkgo interactions. This was because subjects in Stage +2 required fewer trials to complete the task and made fewer errors after ginkgo treatment, whereas those in Stage +1 showed no benefits. Subjects in Stage +2 had poorer performance at baseline compared to those in Stage +1 both in this task and the test of planning ability. The beneficial effects of ginkgo were limited to the test of mental flexibility and to those with poorer performance.

Key Words: attention • frontal lobe function • Ginkgo biloba • memory • mental flexibility • mood • planning • postmenopausal women

Journal of Psychopharmacology, Vol. 19, No. 2, 173-181 (2005)
DOI: 10.1177/0269881105049038


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Lovera, B. Bagert, K. Smoot, C.D. Morris, R. Frank, K. Bogardus, K. Wild, B. Oken, R. Whitham, and D. Bourdette Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial Multiple Sclerosis, April 1, 2007; 13(3): 376 - 385. [Abstract] [PDF]